Supplementation with Abscisic Acid Reduces Malaria Disease Severity and Parasite Transmission

Elizabeth K. K. Glennon, L. Garry Adams, Derrick R. Hicks, Katayoon Dehesh, and Shirley Luckhart*
Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, Davis, California; Department of Veterinary Pathobiology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas; Department of Plant Biology, University of California, Davis, Davis, California

Abstract. Nearly half of the world’s population is at risk for malaria. Increasing drug resistance has intensified the need for novel therapeutics, including treatments with intrinsic transmission-blocking properties. In this study, we demonstrate that the isoprenoid abscisic acid (ABA) modulates signaling in the mammalian host to reduce parasitemia and the formation of transmissible gametocytes and in the mosquito host to reduce parasite infection. Oral ABA supplementation in a mouse model of malaria was well tolerated and led to reduced pathology and enhanced gene expression in the liver and spleen consistent with infection recovery. Oral ABA supplementation also increased mouse plasma ABA to levels that can signal in the mosquito midgut upon blood ingestion. Accordingly, we showed that supplementation of a Plasmodium falciparum-infected blood meal with ABA increased expression of mosquito nitric oxide synthase and reduced infection prevalence in a nitric oxide-dependent manner. Identification of the mechanisms whereby ABA reduces parasite growth in mammals and mosquitoes could shed light on the balance of immunity and metabolism across eukaryotes and provide a strong foundation for clinical translation.

INTRODUCTION

Roughly 3.2 billion people are at risk of malaria.1 Increased drug and insecticide resistance have precipitated the need for novel therapeutics, including treatments with dual therapeutic and transmission-blocking properties. Ideal therapeutics would reduce parasite growth directly by targeting multiple life stages of the Plasmodium parasite or indirectly by enhancing defense responses of both mammalian and mosquito hosts.

The isoprenoid abscisic acid (ABA) was originally characterized as a plant hormone controlling leaf abscission, but has since been detected in a wide variety of eukaryotes including mammals, sponges, and the apicomplexan parasite Toxoplasma gondii.3–5 In these organisms, ABA functions in immune and metabolic processes, including desiccation tolerance in plants, heat stress response in sponges, and insulin release in humans.5–7 ABA also increases cell proliferation, regulating regeneration in hydroids and expansion of human mesenchymal stem cells.8,9 This conservation across eukaryotes led us to hypothesize that ABA might function in the interactions among mammals, mosquitoes, and Plasmodium to alter dynamics of malaria parasite infection and transmission.

In mammals, ABA can be pro- or anti-inflammatory depending on context. For example, treatment with ABA can activate human macrophages in vitro, stimulating phagocytosis and the release of reactive nitrogen and oxygen species (RNOS).8,10 In contrast, ABA supplementation in a mouse model of inflammatory bowel disease (IBD) reduced epithelial erosion and leukocyte infiltration.11 In this context, ABA has been proposed as a supplementary treatment of IBD due to its ability to limit harmful inflammation.12 Accordingly, we hypothesized that complications in malaria such as cerebral pathology and liver dysfunction that can be exacerbated by the host inflammatory response to high parasite levels could be mitigated by ABA supplementation.13,14

In insects, ABA ingested with nectar is detectable in honey bees and supplementation of hives enhanced healing and immune cell activation in treated bees.15 Mosquitoes similarly ingest a variety of bioactive factors during host feeding. In particular, human insulin and transforming growth factor beta in ingested blood can signal in the mosquito midgut to alter parasite infection.16,17 Given that ABA has been detected in human blood in the nanomolar range, we hypothesized that mosquitoes could respond to ingested ABA.7,18 Further, ABA regulation of granulocyte synthesis of RNOS—compounds that are essential to the mosquito immune response to Plasmodium infection—suggested that ABA could regulate analogous mosquito responses to developing parasites.19

Based on these collective observations, we used a mouse model of Plasmodium yoelii 17XNL infection (hereafter P. yoelii) as well as cultured Plasmodium falciparum to investigate the ability of ABA to alter Plasmodium-associated pathology in the mammalian host, parasitemia and the formation of sexual stage gametocytes, as well as transmission of both parasite species to a competent mosquito host Anopheles stephensi.

METHODS

Animals, infection, and histology. Six to eight weeks old female CD1 mice (Jackson) were housed four to a cage and provided with unsupplemented water or water supplemented with 2.56 mM ABA (Sigma-Aldrich, St. Louis, MO). Water and supplemented water were changed daily. On day 3 of supplementation, mice were injected intraperitoneally with 5 × 10⁶ P. yoelii 17XNL-infected red blood cells (RBCs). Mouse weight, water consumption per cage, and parasitemia were monitored daily. Parasitemia was determined from thin blood films stained with Giemsa. Parasitemia was measured as the percentage of infected RBCs divided by total RBCs, whereas gametocytemia was measured as the proportion of gametocyte-containing RBCs of total infected RBCs. Four mice were
used per group in replicated studies. Daily parasitemias and gametocytemias were analyzed by unpaired t test.

Mice were euthanized on day 7 postinfection. Blood was collected by heart puncture, spun at 5,900 × g for 8 minutes and the plasma collected for ABA quantification. Livers and spleens were collected, retained in 10% formalin for 24 hours and then stored in 70% ethanol before sectioning and staining with hematoxylin and eosin. Liver sections were blindly scored on a scale from 0 to 3 for pigment levels, Kupffer cell density, portal tract inflammation, hemozoin deposition, extramedullary hematopoeisis, sinusoidal leukocyte density, sinusoidal adherence of leukocytes, and presence of microabscesses, using an adaptation of the procedure of Roux and others. At 400× and 1,000× (oil immersion) magnification, leukocytes midstream in sinusoidal lumens and not in approximation with the sinusoidal endothelium were classified as nonadherent. Using the same magnifications, nonmidstream leukocytes in tight approximation with the sinusoidal endothelium were classified as adherent.

Spleen sections were blindly scored on a scale from 0 to 3 for hyperplasia, extramedullary hematopoeisis, pigment, and levels of histiocytes and neutrophils. Pathology scores of control and treated mice were analyzed by unpaired t test.

**Ethical statement.** Experiments with mice were carried out in strict accordance with the recommendations in the Guide for Care and Use of Laboratory Animals of the National Institutes of Health and were approved by the Institutional Animal Care and Use Committees at the University of California, Davis under approved protocol 18948.

**ABA extraction and quantification.** ABA was extracted from mouse plasma as described in Engberth and others. Briefly, 50 μL of plasma was added to 200 μL extraction buffer (1-propanol : H2O : concentrated HCl at 2:1:0.002 volume ratio) and vortexed. Five hundred microliter of ethyl acetate was added and the samples were vortexed again. Samples were spun at 10,000×g for 1 minute and the upper layer collected and dried under a steady stream of air. Dried samples were re-eluted in 100% methanol, and ABA levels were determined using the PhytoDetect Abscisic Acid ELISA kit (Agdia, Elkhart, IN) according to the manufacturer’s instructions. ABA levels in the plasma of control and ABA-supplemented mice (N = 4–5 per group) were analyzed by Mann–Whitney test.

ABA was extracted from four independent *P. falciparum* cultures as described with minor adjustments. In brief, infected RBCs (~200 mg) were collected, quickly weighed, and immediately frozen in liquid nitrogen. Frozen samples were finely ground in a mortar and transferred to a 4-mL screw top Supelco vial containing 1,200 μL of 2-propanol/H2O/HCl (2:1:0.002) and sonicated in a water bath for 10 minutes. Dichloromethane (2 mL) was added to each sample and resonicated for 10 minutes. The bottom dichloromethane/2-propanol layer was then transferred to a 4-mL glass vial, evaporated under a constant air stream and the resultant pellet was subsequently dissolved in 300 μL of diethyl ether/methanol (9:1 vol/vol) followed by the addition of 9 μL of a 2.0 M solution of trimethylsilyldiazomethane in hexane to convert the carboxylic acids into methyl esters. During this step, ABA was converted to MeABA. The vials were capped, vortexed, and incubated at room temperature for 25 minutes. After incubation, 9 μL of 12% acetic acid in hexane was added to each sample and samples were incubated at room temperature for another 25 minutes to destroy all excess trimethylsilyldiazomethane.

The resulting methyl ester volatiles were captured on Super-Q (Alltech Inc., State College, PA) columns by vapor-phase extraction as described. The trapped metabolites were then eluted with 150 μL of dichloromethane and analyzed by gas chromatography–mass spectrometry using a Hewlett and Packard 6890 series gas chromatograph coupled to an Agilent Technologies, Santa Clara, CA 5973 network mass selective detector operated in electronic ionization mode. Of the sample, 1 μL was injected in splitless mode at 250°C and separated using an HP-5MS column (30 m × 0.25 mm, 0.25 μm film thickness) held at 40°C for 1 minute after injection, and then at increasing temperatures programmed to ramp at 15°C/minute to 250°C (10 minutes), with helium as the carrier gas (constant flow rate 1.0 mL/minute). Measurements were carried out in selected ion monitoring 190 m/z for MeABA and 194 m/z for MeDiABA (D6 deuterated standard).

**Mosquito rearing and infections.** *Anopheles stephensi* Liston (Indian wild-type strain) were reared and maintained at 27°C and 75% humidity. For all feeding experiments, 3-to 5-day-old female mosquitoes were maintained on water pads for 24 hours and then allowed to blood feed for 30 minutes on control or ABA-supplemented *P. yoelii* 17XNL-infected mice. Cohorts of 50 mosquitoes were allowed to feed on each mouse at 5 days postinfection. Immediately after feeding nonengorged mosquitoes were removed. Ten days postfeeding, midguts were dissected, stained with 0.5% mercurochrome, and oocytes counted by microscopy.

For *P. falciparum* infections, *An. stephensi* were fed on *P. falciparum* cultures diluted 1:1 with uninfected RBCs and heat-inactivated human serum, containing a treatment or diluent control and provided in a Hemotek Insect Feeding System (Discovery Workshops, Accrington, UK). ABA stock was diluted with phosphate-buffered saline (PBS) and added into blood immediately before feeding for final concentrations of 10 and 100 nM. For feeds with *P. falciparum* cultures, mosquitoes were maintained on sugar cubes and water pads containing 1 mg/mL L-NAME methyl ester (L-NAME), mosquitoes were maintained on sugar cubes and water pads containing 1 mg/mL L-NAME, 50 mosquitoes were allowed to feed on each mouse at 5 days postinfection. Immediately after feeding nonengorged mosquitoes were removed. Ten days postfeeding, midguts were dissected, stained with 0.5% mercurochrome, and oocytes counted by microscopy.

Four infection replicates were combined when replicate controls were determined not to be significantly different from each other by analysis of variance. Infection prevalence data were analyzed by Fisher’s exact test. Oocyst intensities were analyzed by Mann–Whitney test.

**Plasmodium falciparum growth assays.** *Plasmodium falciparum* NF54 cultures were synchronized as previously described and aliquots plated in complete RPMI 1640 medium with HEPES, hypoxanthine, and 10% heat inactivated human serum. Parasites were treated with 10 nM ABA, 100 nM ABA, or a diluent control and incubated at 37°C for 48 or 96 hours before culture media were replaced with 10% formalin in RPMI 1640. RBCs were stained with 10 μg/mL propidium iodide (Sigma-Aldrich) in PBS at room temperature for 1 hour and infected cells counted with FACS Calibur flow cytometer (BD Biosciences, San Jose, CA). Four replicates were carried out, each using a separate parasite culture passage. Relative changes in growth were normalized to controls set at one and analyzed by one-sample t test.

Studies of the effects of ABA on gametocyte formation were performed with *P. falciparum* 3D7 engineered to express...
ABA supplementation increased circulating ABA levels and decreased parasitemia, gametocytemia, and disease pathology in *P. yoelii*-infected mice. To determine the effect of ABA on parasite infection and disease pathology, we supplemented the water of female CD1 mice throughout the course of infection with 2.56 mM ABA, equivalent to 100 mg/kg and the lowest dose shown to ameliorate symptoms of influenza, IBD, and type II diabetes in mice.11,12,31–33 Infected ABA-supplemented mice consistently drank more water than controls when water consumption was normalized to account for differences in mouse weight (Supplemental Figure 1A). Among infected mice, daily weight change was not different over the course of infection, although the average weight of control mice began to drop on day 7 while that of ABA-supplemented mice did not (Supplemental Figure 1B). *Plasmodium yoelii* infection had no effect on ABA levels present in mouse plasma (Figure 1A). In the absence of infection, oral ABA supplementation did not alter ABA levels (data not shown). However, in the context of *P. yoelii* infection ABA supplementation increased levels of ABA in plasma over 6-fold compared with nonsupplemented infected mice (Figure 1A), suggesting bioavailability of ABA may be determined by infection status. Within control and treatment groups, ABA levels were not correlated with parasitemia (data not shown).

Parasitemia was significantly reduced in ABA-supplemented mice relative to controls starting on day 4 postinfection and continuing until necropsy on day 7 (Figure 1B). ABA-supplemented mice were also noticeably less lethargic at necropsy compared with controls. In addition to decreased parasitemia, ABA-supplemented mice exhibited reduced gametocytemia, which was significantly different relative to controls on day 6 of infection (Figure 1C). Despite this difference in gametocytemia, no differences in the ratios of male to female gametocytes were evident between control and ABA-treated mice (Supplemental Figure 2).

To define the histologic effects of ABA treatment and the ABA-dependent decrease in parasitemia in tissues relevant to infection, livers and spleens were scored and compared among supplemented and control mice in the presence and absence of parasite infection. Liver damage occurs during erythrocytic *P. falciparum* infection with foci of necrosis correlating with liver dysfunction.34,35 Liver damage has also

---

**RESULTS**

**Gene expression.** For mosquito immune gene expression, 20 mosquitoes in each treatment group were dissected at 1, 2, 4, 6, 8, and 24 hours postfeeding. Midguts were sonicated and stored in 96-well flat-bottomed plates and treated with 10 nM ABA, 100 nM ABA, or an equivalent volume of diluent control. Media and treatments were refreshed every 48 hours. At 4, 6, and 8 days after the start of treatment, separate aliquots were harvested, media were removed, and replaced with 10% formalin for 1 hour at room temperature. Formalin was removed and replaced with PBS before gametocyte levels were measured by flow cytometry using a FACSCalibur flow cytometer (BD Biosciences) with a GFP filter. Four replicates were carried out, each using a separate parasite culture passage. Relative changes in gametocyte numbers were normalized to controls set at one and analyzed by one-sample *t* test.

---

**Figure 1.** Oral supplementation of abscisic acid (ABA) increased plasma ABA levels and decreased parasitemia and gametocytemia in mice. (A) Concentrations of ABA in plasma of uninfected CD1 mice and on day 7 post-*Plasmodium yoelii* infection with and without ABA treatment. Four to five mice were used per group. Data were analyzed using the Mann–Whitney test. (B) Daily percent parasitemia of control and ABA-supplemented mice infected with *P. yoelii*. (C) Gametocytemia, measured as the proportion of gametocytes in infected red blood cells (RBCs). Data for (B) and (C) are shown as means of four mice per group. Daily parasitemia and gametocytemia were analyzed by unpaired *t* test. *P < 0.05, **P < 0.01.
been observed in mice infected with *P. yoelii* 17XNL, *Plasmodium chabaudi*, and *Plasmodium berghei*. In particular, apoptosis of hepatocytes has been shown to be induced by infection-associated oxidative stress and liver metabolic dysfunction can result from immunopathology during malaria. The spleen is crucial to clearance of *Plasmodium*-infected RBCs. Inflammation and hyperplasia, seen during *Plasmodium* infection can impair blood flow through the spleen and lead to organ failure.

In the absence of infection, ABA treatment significantly decreased the number of sinusoidal leukocytes in the liver; this trend, although not significant, was also evident in *P. yoelii*-infected mice (Figure 2A and E). In *P. yoelii*-infected mice, hemozoin deposition, pigment, portal tract inflammation, extramedullary hematopoiesis, and Kupffer cell density were increased relative to controls, but these levels were not altered by ABA treatment (Supplemental Figure 3A). However, the livers of ABA-treated infected mice had significantly fewer adherent leukocytes (Figure 2B and F) and significantly fewer microabscesses than control mice on day 7 postinfection (Figure 2C and G). Further, in ABA-treated mice, parasitemia was significantly inversely correlated with pathology scores for leukocytes and adherent leukocytes (Supplemental Figure 4A and B). In these cases, reduced pathology did not appear to simply follow from reduced parasitemia, but rather the beneficial effects of ABA appeared to be greater at higher parasitemia.

In the absence of parasite infection, spleen scores of ABA-supplemented and control mice were not significantly different (Figure 2D, Supplemental Figure 3B). In *P. yoelii*-infected mice, histiocyte density, pigment deposition, and extramedullary hematopoiesis in the spleen were increased relative to control mice, but these changes were not altered by ABA treatment (Supplemental Figure 3B). However, lymphoid hyperplasia of the spleen, which was increased in infected mice, was reduced by ABA treatment in three of four mice (Figure 2D and H). Consistent with this ABA-dependent reduction in inflammatory pathology, we observed

![Figure 2](image-url)

**Figure 2.** Oral supplementation of abscisic acid (ABA) decreased tissue inflammatory responses of *Plasmodium yoelii* infected mice. 
(A) The livers of *P. yoelii* infected mice had significantly more nonadherent sinusoidal leukocytes than uninfected controls. ABA reduced the hepatic nonadherent leukocytes of uninfected mice, but failed to significantly reduce the hepatic nonadherent leukocytes of infected mice. 
(B) The livers of *P. yoelii* infected mice again had significantly more adherent sinusoidal leukocytes than uninfected controls. ABA had no effect on the hepatic adherent leukocytes of uninfected mice, but highly significantly reduced the hepatic adherent leukocytes of *P. yoelii* infected mice. 
(C) The livers of *P. yoelii* infected mice had significantly more microabscesses than uninfected controls. ABA had no effect on the splenic microabscesses of uninfected mice, but highly significantly reduced the hepatic microabscesses of *P. yoelii* infected mice. 
(D) The spleens of *P. yoelii* infected mice had significantly more lymphoid hyperplasia of periarteriolar lymphoid sheaths than uninfected controls. ABA had no effect on the splenic lymphoid hyperplasia of uninfected mice, but showed a trend, though not statistically significant, toward reducing splenic lymphoid hyperplasia of *P. yoelii* infected mice. 
(E) Liver sections with arrows indicating sinusoidal nonadherent leukocytes. 
(F) Liver sections with arrows indicating adherent sinusoidal leukocytes. 
(G) Liver sections with a sinusoidal microabscess indicated by the arrow. 
(H) Spleen sections with lymphoid hyperplasia of the periarteriolar lymphoid sheaths indicated by arrows. Bars = 100 μm; Py = *P. yoelii*-infected; Uninf = uninfected.
decreased transcript levels of nitric oxide synthase (NOS) and increased transcript levels of the anti-inflammatory regulator peroxisome proliferator activated receptor gamma (PPARγ), which are regulated by ABA, in both the liver and spleen (Figure 3).11,12,30,31

**ABA supplementation of mice reduced *P. yoelii* transmission to mosquitoes.** The effect of ABA on gametocytemia led us to investigate the effect of ABA supplementation on transmission of parasites from mice to mosquitoes. In these studies, ABA-supplemented mice again showed reduced parasitemia compared with controls starting on day 3 (Figure 4A) and significantly reduced gametocytemia on day 5 postinfection (Figure 4B), near peak gametocytemia. On day 5, each mouse in the ABA-supplemented and control groups was exposed to 50 female *An. stephensi*. Ten days later, mosquito midguts were dissected and oocysts counted to measure mosquito infection prevalence and intensity. The prevalence of infected mosquitoes that fed on control mice was 88.8% (mean of 15 oocysts per midgut) compared with an infection prevalence of 60.9% of mosquitoes that fed on ABA-supplemented mice (mean of 12 oocysts per midgut) (Figure 4C and D). Although the difference in mean oocysts per midgut was significant, the effect was small. However, the 31.4% reduction in prevalence is notable and, given that a single oocyst can produce sufficient sporozoites for transmission to a human host, is arguably a more relevant measure for malaria control.

**ABA does not alter *P. falciparum* growth and gametocyte development in vitro.** The observed decreases in *P. yoelii* parasitemia and gametocytemia observed with ABA treatment (Figure 1B and C) could be due to a direct effect of ABA on parasite growth and development, an indirect effect on the parasite through alterations in host physiology and immunity, or a combination of both. Further, circulating ABA levels (in the absence of supplementation; Figure 1A) could derive from host or parasite synthesis or both. To address these possibilities, we used in vitro cultures of *P. falciparum* to minimize host-derived synthesis of ABA and to extend our observations beyond the mouse model.

In four separate cultures, we were unable to detect ABA by either enzyme-linked immunosorbent assay or mass
spectrometry in approximately $1.7 \times 10^9$ pooled RBCs per culture (mean of 8% parasitemia). Based on the potential for direct exposure of parasites to ABA after transport across the RBC plasma membrane and on circulating levels of ABA in unsupplemented and supplemented infected mice (Figure 1A), we treated cultures of *P. falciparum* with 10 nM ABA, 100 nM ABA, or an equivalent volume of diluent control to assess the effects of ABA on parasite development. At 48 and 96 hours after treatment, ABA had no effect on asexual growth relative to untreated control cultures (Figure 5A). In addition, treatment with ABA had no effect relative to controls on gametocyte levels at 6, 8 or 10 days postculture synchronization, when gametocytogenesis is initiated (Figure 5B). These observations suggested that ABA-dependent decreases in parasitemia and gametocytemia in the mouse and decreased transmission to mosquitoes were not caused by direct effects of ABA on the parasites but rather the effects of ABA were likely due to indirect effects on mouse, and possibly mosquito, physiology.

**Supplementation of ABA in a *P. falciparum*-infected blood meal reduced transmission to *An. stephensi* by increasing nitric oxide production in the mosquito midgut.** Although gametocytemia was reduced with ABA supplementation in infected mice (Figure 1C), it was unclear whether decreased
transmission (Figure 4C and D) was due solely to this effect on gametocytemia or to a combination of reduced gametocytemia and effects of ingested ABA on \textit{An. stephensi}.

To isolate the effects of ABA on the mosquito host, we supplemented gametocyte cultures of \textit{P. falciparum} with 10 nM ABA, 100 nM ABA, or an equivalent volume of diluent as a control immediately prior to feeding to \textit{An. stephensi}. Mosquitoes were dissected at 10 days after feeding to record infection prevalence and intensity. Supplementation with 10 nM or 100 nM ABA reduced infection prevalence in \textit{An. stephensi} by 30% and 36%, respectively, relative to control (Figure 6A). Notably, these reductions were consistent with the reduction in the prevalence of infected mosquitoes fed on ABA-supplemented, \textit{P. yoelii}-infected mice relative to controls (31.4%, Figure 4C). Though the reduction in infection prevalence was greater with 100 nM ABA, the difference between the two treatment concentrations was not statistically significant. Among \textit{P. falciparum}-infected mosquitoes, mean oocysts per midgut decreased significantly from 2.1 in controls to 1.6 with 10 nM ABA (Figure 6B).

To discern how ABA might be reducing \textit{P. falciparum} infection in \textit{An. stephensi}, we examined transcript levels of the gene encoding the antimicrobial peptide defensin as well as those encoding the antiparasite effectors \textit{AsNOS} and the complement-like proteins LRIM, APL1, and TEP1.27,45,46 Mosquitoes were provided with a \textit{P. falciparum}-infected blood meal supplemented with 100 nM ABA or with an equivalent volume of diluent as control, then analyzed at 1–24 hours postfeeding. ABA treatment led to a small increase in \textit{defensin} mRNA levels at 4 hours (Supplemental Figure 5A) and increased \textit{APL1} expression at 4 and 8 hours postfeeding to levels that approached statistical significance (Supplemental Figure 5C). However, the most notable response to supplementation with ABA was increased \textit{AsNOS} expression. \textit{AsNOS} transcript levels were induced up to 13-fold in the midguts of ABA-treated mosquitoes relative to controls between 4–6 hours postfeeding (Figure 6C). Given that nitric oxide (NO) is a critical parasite-killing factor in \textit{An. stephensi}, we reasoned that ABA-dependent increased NO synthesis could contribute to observed differences in infection between ABA-treated and control mosquitoes. To test this hypothesis, we provided \textit{P. falciparum}-infected blood meals to \textit{An. stephensi} with 100 nM ABA, with ABA and 1 mg/mL of the NOS inhibitor L-NAME, the inhibitor alone, or with an equivalent volume of ABA and inhibitor diluents as a control.45–47 Addition of L-NAME to an ABA-supplemented infected blood meal rescued \textit{P. falciparum} infection prevalence back to control levels, whereas the inhibitor alone had no effect on infection (Figure 6D). Complete inhibition of the effect of ABA on infection suggested that ABA-dependent NO synthesis reduced parasite survival in the mosquito midgut.

**Figure 6.** Abscisic acid (ABA) supplementation of a \textit{Plasmodium falciparum}-infected blood meal reduced infection prevalence in \textit{Anopheles stephensi} by increasing nitric oxide production. (A) Mean proportions of mosquitoes that became infected upon feeding on \textit{P. falciparum}-infected blood meals supplemented with 10 nM ABA, 100 nM ABA, or with an equivalent volume of diluent as a control. Bars represent four replicates with separate cohorts of mosquitoes. Data were analyzed by Fisher’s exact test. (B) Oocysts per midgut of mosquitoes that were infected; medians are shown. Data were analyzed by the Kruskal–Wallis test followed by Dunn’s multiple comparison test. (C) Fold change in \textit{An. stephensi} nitric oxide synthase expression in the midgut of mosquitoes fed a \textit{P. falciparum}-infected blood meal supplemented with 100 nM ABA. Each dot represents a replicate of 10 pooled midguts. Data are shown as fold change (2\textsuperscript{ΔΔC}t) in gene expression relative to control-supplemented \textit{P. falciparum}-fed mosquitoes. Data were analyzed by one-sample \(t\) test. (D) Mean proportions of mosquitoes that became infected upon feeding on \textit{P. falciparum}-infected blood meals supplemented with 100 nM ABA, N\textsubscript{ω}-Nitro-L-arginine methyl ester (L-NAME), 100 nM ABA + L-NAME or an equivalent volume of diluent as a control. Bars represent four replicates with separate cohorts of mosquitoes. Data were analyzed by Fisher’s exact test. * \(P \leq 0.05\), ** \(P \leq 0.01\), *** \(P \leq 0.005\).
DISCUSSION

We have shown that oral ABA supplementation reduced *P. yoelii* parasitemia and gametocytemia, the pathology associated with higher parasite loads, and parasite transmission to the mosquito *An. stephensi*. Hence, ABA supplementation limited growth and development of *P. yoelii* life stages in two different hosts: asexual growth and gametocyte formation in the mammalian host and survival to oocyst formation in the mosquito host. The lack of a direct effect on *P. falciparum* asexual growth or gametocyte formation in vitro suggests that ABA alters the biology of both the mammalian and insect hosts to limit infection and transmission.

The effect of ABA on inflammatory pathology in the mouse liver and spleen could derive from a direct, restorative effect of ABA on these tissues or from significantly reduced parasitemia. In a mouse model of influenza, ABA treatment decreased vascular infiltrates, but had no effect on viral load. Similarly, we saw a reduction in leukocyte infiltration into the liver with ABA treatment in the absence of infection, suggesting that ABA can directly affect some host responses independently of its effect on pathogen load. The negative correlation between liver leukocytes and parasitemia in ABA-treated mice also suggests that ABA can directly affect immune cell infiltration in a manner that is influenced by pathogen load and existing pathology. Indeed, previous studies have demonstrated that the effects of ABA can be context-dependent. In particular, ABA stimulates insulin release in a glucose concentration-dependent manner and can enhance or suppress nuclear factor-kappa B (NF-κB) activity depending on cell type. Here, we speculate that the reduction in pathology in our mouse model is likely due to a combination of the direct effects of ABA on host tissues and the reduction in parasitemia.

The reduction in liver and spleen pathology corresponded to increased *PPARγ* expression in both tissues on day 7 of infection (Figure 3). ABA induces *PPARγ* expression and this is required for its beneficial effects in the context of widely different conditions: decreased pathology in models of IBD, enhanced insulin sensitivity, and extended mouse lifespan during influenza infection. *PPARγ* is notable in the context of malaria because of its ability to limit inflammation-based pathology while also increasing pathogen clearance. In particular, enhanced *PPARγ* activity has been shown to increase CD36-mediated phagocytosis of *P. falciparum*-infected RBCs and the *PPARγ* agonist rosiglitazone was shown to enhance parasite clearance and reduce inflammation biomarkers in a human trial. The reduction in leukocyte adherence in the liver with ABA treatment (Figure 2B) corresponds with increased *PPARγ* transcript levels (Figure 3), which supports the use of *PPARγ* agonists as adjunctive treatments for severe malaria. By extension, ABA supplementation, through these beneficial effects on *PPARγ*, could be used to ameliorate symptoms of severe or complicated malaria.

The reduction in liver and spleen pathology also corresponded to decreased *NOS* expression in both tissues on day 7 of infection (Figure 3). The impact of *NOS* expression in malaria is tissue specific and time specific. For example, early *NOS* expression in the spleen, but not in the liver, was shown to correlate with resistance to blood-stage *P. chabaudi*. In addition, during lethal *P. berghei* infection, inducible *NOS* mRNA levels in the liver decreased as parasitemia rose but then increased later in infection when mice were close to death. Here, failure to clear parasites was associated with increased inducible *NOS* expression in the liver late during infection. In the context of the observed reduction in tissue pathology and increased *PPARγ* transcript levels, it is likely that decreased *NOS* expression in the liver and spleen of ABA-supplemented mice on day 7 of infection reflects recovery from inflammation.

In contrast to later resolution of inflammation in the mouse, ingestion of ABA by the mosquito induced high levels of *AsNOS* expression within 4–6 hours after infection, a response that likely targets newly formed ookinetes in the midgut lumen. Coincident with this response were induced levels of defensin and *APL1* transcripts, suggesting that ABA signaling regulates NF-κB-dependent gene expression in a manner analogous to that observed in mammalian cells. The impact of immune genes other than *AsNOS*, however, remains to be determined. Given the significant reduction in parasitemia in ABA-treated mice by 3–4 days postinfection (Figures 1B and 4A), ABA may function to promote early inflammatory responses in both hosts to reduce parasite development and then feedback to promote restoration from inflammation as observed in the mouse.

The development of drugs to target multiple parasite life stages has been identified as a crucial goal for future antimalarials. We have shown that dietary supplementation with ABA reduced infection, pathology, and transmission in malaria. ABA is a natural part of the human diet, present for example in honey and spinach. Magnone and others found that the consumption of fruits with high ABA content increased plasma ABA levels and reduced glycemia in rats and humans compared with glucose-fed controls. No harmful effects have been reported to date for ABA supplementation, although how ABA supplementation interacts with other treatments and to what extent the effects of ABA can be enhanced will be the focus of future studies. Importantly, identification of the mechanisms whereby ABA alters mosquito physiology and transmission as well as inflammation and health of the mammalian host could shed light on the balance of immunity and metabolism across eukaryotes and provide a strong foundation for clinical and public health translation.

Received December 16, 2015. Accepted for publication January 29, 2016.

Published online March 21, 2016.

Note: Supplemental figures appear at www.ajtmh.org.

Acknowledgments: We thank Kong Cheung (Department of Medical Microbiology and Immunology, University of California, Davis) for assistance with mosquito infection studies and *Plasmodium falciparum* growth assays. We also thank Rashan Potts (Department of Medical Microbiology and Immunology, University of California, Davis) for assistance with mouse infections.

Financial support: This work was supported by the University of California, Davis College of Biological Sciences Dean’s Kingdom Crossing Project, funded by the Stanley and Jacqueline Schilling Endowment. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Disclosure: Shirley Luckhart and Elizabeth K. K. Glennon are authors on a provisional patent.

Authors’ addresses: Elizabeth K. K. Glennon and Shirley Luckhart, Department of Medical Microbiology and Immunology, University of California, Davis, Davis, CA, E-mails: ekglennon@ucdavis.edu and sluckhart@ucdavis.edu. L. Garry Adams, Department of Veterinary
Pathobiology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, E-mail: gadams@cvm.tamu.edu. Derrick R. Hicks, Department of Plant Pathology, University of California, Davis, Davis, CA, E-mail: dhicks1@uw.edu. Katayoon Dehesh, Department of Plant Biology, University of California, Davis, Davis, CA, E-mail: kdehesh@ucdavis.edu.

REFERENCES


ABSCISIC ACID AND MALARIA


